All In Biotech

Drug Trial Radar · NCT00853242

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis

Last checked: Nov 20, 2026Latest source record: May 1, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 349 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

349

Actual

Start

Feb 2009

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Mar 2, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease participants on hemodialysis.

Conditions

  • Kidney Failure, Chronic

Interventions

  • PlaceboDrug

  • Genz-644470Drug

  • Sevelamer carbonateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Serum Phosphorus at Day 22 (Genz-644470 vs Placebo)Time frame: Baseline, Day 22

Locations

53 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Alexander City, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Hot Springs, Arkansas

  • Site not named

    Bakersfield, California

  • Site not named

    Los Angeles, California

  • Site not named

    Paramount, California

  • Site not named

    Pembroke Pines, California

  • Site not named

    Porterville, California

  • Site not named

    Riverside, California

  • Site not named

    San Dimas, California

  • Site not named

    Whittier, California

  • Site not named

    Denver, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Hudson, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Gurnee, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Wichita, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Bethesda, Maryland

  • Site not named

    Pontiac, Michigan

  • Site not named

    Southfield, Michigan

  • Site not named

    Brookhaven, Mississippi

  • Site not named

    Gulfport, Mississippi

  • Site not named

    St Louis, Missouri

  • Site not named

    Kearney, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Bellmore, New York

  • Site not named

    Brooklyn, New York

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Port Washington, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Doylestown, Pennsylvania

  • Site not named

    Lancaster, Pennsylvania

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.